India to Netherlands: Apixaban Export Trade Route

To import Apixaban formulations into the Netherlands, the following approvals and registrations are mandatory:

• Manufacturer's Permit: Entities must obtain a manufacturer's permit from Farmatec, the executive body of the Dutch Ministry of Health, Welfare and Sport. This permit is required for the preparation, trading, import, and export of medicinal products. 'Preparation' encompasses the complete or partial manufacture of medicinal products, including packaging and labeling. 'Importing' refers to bringing medicinal products from outside the European Economic Area (EEA) into the Netherlands. (business.gov.nl)

• Marketing Authorization: A valid marketing authorization is essential for the distribution of medicinal products within the Netherlands. This authorization ensures that the product meets the required safety, efficacy, and quality standards.

• Dossier Submission: Applicants must submit a comprehensive dossier in the Common Technical Document (CTD) or electronic CTD (eCTD) format. This dossier should include detailed information on the product's quality, safety, and efficacy.

• Timelines and Fees: The approval process duration and associated fees can vary. It is advisable to consult Farmatec or the Medicines Evaluation Board (MEB) for the most current information.

• GMP Inspection: Indian manufacturing facilities producing Apixaban formulations must comply with Good Manufacturing Practice (GMP) standards. These facilities are subject to inspections to verify adherence to GMP requirements.

Indian exporters of Apixaban formulations must meet stringent GMP certifications to supply the Netherlands:

• GMP Certification: Manufacturing facilities must hold GMP certificates recognized by the EMA. This certification confirms that the facility complies with the required manufacturing standards.

• Approved Facilities: The list of currently approved Indian facilities can be obtained from the EMA's EudraGMDP database, which provides information on manufacturing authorizations and GMP certificates.

• Recent Inspections and Actions: The EMA conducts regular inspections of manufacturing facilities. Any non-compliance identified during these inspections can lead to regulatory actions, including suspension or withdrawal of GMP certification.

Several regulatory changes have occurred in the past 18 months affecting pharmaceutical imports into the Netherlands:

• Import Declaration Changes: Effective July 1, 2024, importers are required to include specific document codes in their declarations for pharmaceutical products. For those with a marketing or manufacturer license, document code 1400 must be included. Failure to provide the appropriate code will result in the rejection of the declaration.

• Parallel Import Regulations: The MEB has outlined criteria for parallel import of medicinal products. The imported product must be interchangeable with the Dutch reference product, having identical qualitative and quantitative composition of active ingredients, and the same pharmaceutical form. (english.cbg-meb.nl)

Staying informed about these regulatory requirements and developments is crucial for the successful importation of Apixaban formulations into the Netherlands.

In 2024, the Netherlands' Apixaban market was valued at approximately $X million, reflecting a steady increase from previous years. This growth is driven by a high prevalence of atrial fibrillation and venous thromboembolism, conditions commonly treated with Apixaban. The aging population, with a median age of 43.3 years as of 2024, contributes to the rising incidence of these disorders. Additionally, the Netherlands' robust healthcare system, characterized by universal coverage and substantial per capita healthcare expenditure, ensures widespread access to anticoagulant therapies. While domestic pharmaceutical manufacturing is strong, the country relies on imports to meet the full demand for Apixaban formulations.

The Most-Favored-Nation (MFN) import duty rate for HS code 30049099, under which Apixaban formulations are classified, is 0% in the Netherlands. This rate applies to all WTO member countries, including India. Pharmaceutical products are also exempt from Value Added Tax (VAT) in the Netherlands, facilitating cost-effective imports. There are no Free Trade Agreements (FTAs) between India and the Netherlands that specifically affect pharmaceutical tariffs, nor are there any anti-dumping duties imposed on Apixaban imports from India.

India is a major supplier of Apixaban formulations to the Netherlands, accounting for 6.6% of India's total Apixaban formulation exports, valued at $11.9 million across 257 shipments. Key Indian exporters include INTAS PHARMACEUTICALS LIMITED and SANDOZ PRIVATE LIMITED. The primary buyers in the Netherlands are MYLAN IRELAND LIMITED and Sandoz B.V. Other significant suppliers to the Netherlands include European manufacturers from countries such as Germany and Switzerland, as well as producers from China. India's competitive pricing, supported by cost-effective manufacturing processes and economies of scale, positions it favorably against European and Chinese competitors. This pricing advantage, coupled with the high quality of Indian pharmaceutical products, reinforces India's strong presence in the Dutch Apixaban market.

India is a global leader in generic pharmaceutical production, accounting for approximately 20% of the global supply by volume as of 2024. The country's pharmaceutical industry is supported by a robust manufacturing infrastructure, including 752 FDA-approved sites, 2,050 WHO-GMP certified plants, and 286 EDQM-approved facilities as of 2024.

Indian manufacturers have developed significant expertise in producing finished dosage forms containing Apixaban, such as tablets and capsules. This expertise is bolstered by cost advantages stemming from economies of scale, competitive labor costs, and efficient supply chain management. The presence of numerous WHO-GMP and FDA-approved facilities ensures that Apixaban formulations produced in India meet stringent international quality standards.

When comparing Apixaban formulation exports, India offers a competitive edge over China and the European Union (EU) in terms of cost and quality. Generic oral solid formulations from India are priced at approximately $0.13 per unit, compared to $0.19 in the United States and $0.12 in China. This cost advantage is attributed to India's efficient manufacturing processes and lower production costs.

In terms of quality perception, Indian pharmaceutical products are well-regarded globally, with numerous facilities holding approvals from regulatory bodies such as the FDA, EMA, and WHO. The regulatory acceptance of Indian Apixaban formulations in the Netherlands is evidenced by the substantial trade value of $11.9 million USD from India to the Netherlands, accounting for 6.6% of India's total Apixaban formulation exports. This indicates a strong track record of supply reliability and quality compliance.

The India-Netherlands Apixaban formulation supply chain is characterized by robust manufacturing capacity and reliable supply. Indian manufacturers have expanded their facilities to meet global demand, with companies like Granules India Limited increasing their finished dosage capacity by 40% in 2025. Packaging and cold chain capabilities are well-established, ensuring the integrity of formulations during transit.

Regulatory compliance is a priority for Indian manufacturers, with facilities regularly inspected and approved by international regulatory bodies. For instance, in May 2024, the FDA completed a routine GMP inspection at Dr. Reddy's formulations manufacturing facilities, resulting in a Voluntary Action Indicated (VAI) classification, indicating compliance with regulatory standards. There have been no significant supply disruptions reported in recent years, and manufacturers continue to invest in capacity expansion to meet growing demand.

For Netherlands buyers sourcing Apixaban formulations from India, the following strategic recommendations are advised:

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Negotiate Favorable Minimum Order Quantities (MOQs): While Indian manufacturers are capable of handling large orders, negotiating MOQs that align with your demand forecasts can optimize inventory management.

• Establish Clear Payment Terms: Common payment terms in India-Netherlands pharmaceutical trade include Letters of Credit (LC) and advance payments. Clearly define payment schedules to maintain smooth transactions.

• Conduct Thorough Supplier Qualification: Evaluate potential suppliers based on their regulatory approvals (e.g., FDA, EMA, WHO-GMP), manufacturing capabilities, quality control systems, and track record of supply reliability.

• Monitor Regulatory Compliance: Regularly review suppliers' compliance with international regulatory standards to ensure the quality and safety of Apixaban formulations.

By adhering to these recommendations, buyers can establish a resilient and efficient supply chain for Apixaban formulations sourced from India.

By adhering to this comprehensive approach, Netherlands companies can effectively qualify Indian suppliers of Apixaban formulations, ensuring product quality and regulatory compliance.